NCT02538653

Brief Summary

This study aimed at determining the 4-hours postprandial blood glucose and insulin responses to the ingestion of cereal product differing by their SDS content.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
20

participants targeted

Target at below P25 for not_applicable

Timeline
Completed

Started Sep 2015

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 31, 2015

Completed
1 day until next milestone

Study Start

First participant enrolled

September 1, 2015

Completed
1 day until next milestone

First Posted

Study publicly available on registry

September 2, 2015

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2015

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2015

Completed
Last Updated

September 14, 2017

Status Verified

September 1, 2017

Enrollment Period

3 months

First QC Date

August 31, 2015

Last Update Submit

September 13, 2017

Conditions

Keywords

glycemic & insulin response, SDS, cereal product, Nutrition

Outcome Measures

Primary Outcomes (1)

  • Postprandial changes in plasma glucose levels over 2 hours (iAUC [0-120 min]) after consumption of the test products

    2 hours after food consumption

Secondary Outcomes (2)

  • Postprandial changes in glycaemia over 3 hours (iAUC [0-180]), 4h (iAUC[0-240]), during the second part of the morning (iAUC [120-240] and iAUC[180-240]) following the intake of the test products will be analysed.

    4 hours after food consumption

  • Postprandial changes in insulinemia over 2 hours (iAUC [0-120]), over 3 hours (iAUC [0-180]), 4 hours (iAUC[0-240]), during the second part of the morning (iAUC [120-240] and iAUC [180-240]) following the intake of the test products will be analysed.

    4 hours after food consumption

Other Outcomes (2)

  • The plasma glucose peak value and the time for this latter will also be calculated.

    4 hours after food consumption

  • The plasma insulin peak value and the time for this latter will also be calculated.

    4 hours after food consumption

Study Arms (2)

Sandwich biscuits high in SDS

EXPERIMENTAL

50 g of sandwich product with high level of SDS together with a glass of 250 mL of Evian water.

Other: Sandwich biscuit high in SDS

Co-extruded cereals low in SDS

ACTIVE COMPARATOR

48.3 g of co-extruded cereals low in SDS together with a glass of 250 mL of Evian water.

Other: Co-extruded cereal low in SDS

Interventions

Consumption of the high SDS product (50g) alone with a glass of water

Sandwich biscuits high in SDS

Consumption of the low SDS product (48.3 g) alone with a glass of water

Co-extruded cereals low in SDS

Eligibility Criteria

Age18 Years - 45 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Aged between 18-45 years.
  • Non-smoker.
  • BMI values between 19-30 kg/m2 (bounds included). Around half of the subjects will be normal weight and the other half overweight.
  • Ethnicity. Subjects should have the closest characteristics compared to the American population. Not less than 75% but not more than 90% of the subjects should be Caucasian. Not more than 10% of the subjects will be of Asian or Asian Indian descent. The remaining subjects will be from other ethnic groups except from Australian Aborigines.
  • Healthy subjects with:
  • Normal glucose tolerance (fasting blood glucose \< 6.0 mmol/L during the first test session and results of oral glucose tolerance test conducted within the last 30 days within recommendations (fasting blood glucose \< 6.0 mmol/L, 120 minute glucose \< 8.9 mmol/L))
  • Normal laboratory values for various measures of metabolic health (full blood count, gamma-GT, AST, ALT, glucose, TAGs, total cholesterol, HDL-cholesterol, LDL-cholesterol);
  • Normal systolic blood pressure (100-150 mmHg);
  • Normal diastolic blood pressure (60-90 mmHg);
  • Normal resting heart rate (50-90 beats per minutes after 3 minutes rest).
  • Stable dietary habits; normal eating patterns; no history of eating disorders or strict dieting.
  • Moderate level of physical activity (from basic daily activity to a high level of physical activity (regular physical activity at least 3 times per week)
  • Able to fast for at least 10 hours the night before each test session
  • Able to refrain from eating legumes and drinking alcohol the day before each test session.
  • Subject covered by social security or covered by a similar system
  • +2 more criteria

You may not qualify if:

  • Following a restrictive diet.
  • Family history of Diabetes Mellitus or obesity
  • Suffering from any clinical, physical or mental illness.
  • Suffering from any food allergies or hypersensitivities (wheat, milk, egg, nuts, etc).
  • Subject from the Australian Aboriginal ethnicity.
  • Female who is pregnant (positive test results), lactating, planning pregnancy or not using acceptable contraceptive.
  • Females who consistently suffer from premenstrual tension and marked changes in appetite during their menstrual cycle.
  • Subject having taken part in another clinical trial within the last week.
  • Subject in a situation which in the investigator's opinion could interfere with optimal participation in the present study or could constitute a special risk for the subject.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Sydney

Sydney, New South Wales, 2006, Australia

Location

MeSH Terms

Conditions

Metabolic DiseasesShwachman-Diamond Syndrome

Condition Hierarchy (Ancestors)

Nutritional and Metabolic DiseasesExocrine Pancreatic InsufficiencyPancreatic DiseasesDigestive System DiseasesCongenital Bone Marrow Failure SyndromesBone Marrow Failure DisordersBone Marrow DiseasesHematologic DiseasesHemic and Lymphatic DiseasesLipid Metabolism, Inborn ErrorsLipid Metabolism DisordersLipomatosis

Study Officials

  • Jennie Brand Miller

    University of Sydney

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 31, 2015

First Posted

September 2, 2015

Study Start

September 1, 2015

Primary Completion

December 1, 2015

Study Completion

December 1, 2015

Last Updated

September 14, 2017

Record last verified: 2017-09

Locations